OPEN END TURBO OHNE STOP-LOSS - ASTRAZENECA | Market Closed - Börse Stuttgart 11:38:09 25/06/2024 am IST | ||
| 4.98 EUR | +0.40% |
|
| Current month | +11.91% | ||
| 1 month | +3.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 25/24/25 | 4.98 | +0.40% |
| 24/24/24 | 4.96 | +2.27% |
| 21/24/21 | 4.85 | +0.41% |
| 20/24/20 | 4.83 | +0.21% |
| 19/24/19 | 4.82 | -3.41% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:38 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Lang & Schwarz |
| WKN | LX0L7D |
| ISIN | DE000LX0L7D9 |
| Date issued | 18/05/2021 |
| Strike | 98.41 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.22 € |
|---|---|
| Lowest since issue | 0.22 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159
USD
Average target price
174.4
USD
Spread / Average Target
+9.68%
- Stock Market
- Certificates
- Certificat
